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In clinical trials the selection of appropriate outcomes is crucial to the assessment of whether one intervention is better than another. Selection of inappropriate outcomes can compromise the utility of a trial. However, the process of selecting the most suitable outcomes to include can be complex.
Ideally glaucoma trials aim to evaluate important outcomes for clinicians and patients.  A high variability in the selection of outcomes suggests that there is no consensus on how best to evaluate the effect of glaucoma interventions. Further, it makes evidence synthesis difficult.  The purpose of this review is to determine the extent of clinical outcome measures used in published glaucoma Cochrane Reviews and Protocols 
Methods
A systematic review was conducted (up to February 2012) of all Cochrane Reviews and Protocols related to glaucoma interventions and published in English language.  All clinical, patient-reported, as well as economic outcomes were included. 
Results
In the Cochrane Library there were 12 Reviews and 9 Protocols on glaucoma. A total of 118 clinical outcomes were reported. IOP was the most commonly used clinical outcome (n=40), and it was used in 11 Reviews and five Protocols.IOP was evaluated in many different ways; the most common one was a composite definition of success.  Safety outcomes were also frequently reported.  Visual field progression or change was reported in 6 reviews and 3 protocols, but in 13 different ways.  Patient-reported quality of life measures were chosen as main outcome measure in one Review.
Conclusion
There is a large variability in outcomes selected in glaucoma Cochrane Reviews and Protocols.  This heterogeneity in outcome selection impairs the ability for evidence synthesis. There is an urgent need for standardisation of outcomes used in glaucoma trials.
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"Clinical trials are only as credible as their endpoints"(1). Clinical trials usually seek to evaluate whether an intervention is effective and safe. This is determined by comparing the effects of interventions on outcomes chosen to identify the beneficial and harmful effects. There is an increasing recognition that insufficient attention has been paid to the selection of the outcomes to measure in clinical trials. Outcomes need to be relevant to patients, clinicians and policy-makers if the findings of research are to influence practice, policy and future research (2). 
The careful selection of appropriate outcomes is therefore crucial to the design of randomised controlled trials (RCTs) (3). A high variability in the selection of outcomes for glaucoma trials and systematic reviews would suggest that there is no consensus on how best to evaluate the effect of glaucoma interventions. Besides, systematic reviews are hampered by variations in outcomes assessed and reported in otherwise eligible studies. Inconsistent choice of outcome measures means that many meta-analyses are unable to include data from all the relevant studies (2). 
This study was conducted to describe the variability of outcome measures in glaucoma RCTs in the literature, specifically within the Cochrane Library. The Cochrane Library is a collection of six databases that contain different types of high quality, independent evidence to inform healthcare decision-making, and a seventh database that provides information about groups in The Cochrane Collaboration. Cochrane Reviews have generally been shown to be of higher methodological quality than other reviews (4). A Cochrane Review begins with a well-framed question to specify the types of population, interventions, and the outcomes of interest. The three bibliographic databases generally considered to be the most important sources to search for studies for inclusion in Cochrane Reviews are CENTRAL, MEDLINE and EMBASE. National, regional and subject-specific databases should be selected for searching according to the topic of the review. Conference abstracts and other grey literature can be an important source of studies for inclusion. Cochrane Reviews should include outcomes that are likely to be meaningful, including definition (diagnostic method), timing and unit of measurement. The investigators should include adverse as well as beneficial outcomes and decide in advance whether to collect information about all outcomes measured in a study, or about only those pre-specified in the Review. However, they may be faced by variability in the outcomes studied (5). This heterogeneity may be explored by conducting subgroup analyses or meta-regression. It is important to be familiar with the type of data (e.g. dichotomous, continuous) that result from measurement of an outcome in an individual study, and to choose suitable effect measures for comparing intervention groups. Further, it is not advisable to combine outcomes that are too diverse. Decisions concerning what should and should not be combined are inevitably subjective, and require discussion and clinical judgment.(6)
Methods
We searched the Cochrane Databases of Systematic Reviews (which contains the Cochrane Eyes and Vision Group Trials Register) in The Cochrane Library. All published Cochrane Reviews and Protocols in glaucoma were included in our review for data synthesis. The databases were searched in February 2012.
Data were tabulated to collect information on clinical, patient-reported, and economic outcomes, type of intervention and duration of follow up. We recorded detailed information on outcomes and whether designated to be main (primary) or secondary (see table 1) (7-27)
One investigator (RI) independently collected the data, which were reviewed by a second investigator (AAB). Any disagreement was resolved by discussion.
Expected outcomes were grouped into eight main domains: intraocular pressure (IOP), visual field (VF), safety outcomes, haemodynamics (ocular & systemic), anatomical changes, aqueous humour (AH) dynamics, surgical outcomes and persistence/ adherence to therapy. Outcomes (subdomains) were further divided into outcome measures (specific measurement, specific metric or methods of aggregation). For example, for IOP, the pre-defined subdomains were:
(1) 	IOP level 
(i) Mean IOP, mean diurnal IOP, or 24-hour IOP
(ii) Level of IOP variability (range/fluctuation)
(iii) Other unspecified descriptions of the level of IOP
(2) IOP change from baseline
(i) Mean change of IOP compared with baseline, or mean change of diurnal IOP or 24-hour IOP
(ii) Change of IOP variability (range/ fluctuation) from baseline,
(iii) Other descriptors of change of IOP from baseline
(3) Composite definition of success/failure using IOP as part of the definition
 (i) IOP with or without medication, target IOP, percentage reduction of IOP 
(ii) IOP after provocation test  
(iii) Other definition of success/failure (e.g., number of postoperative medications) 
(4) Other descriptions of IOP outcomes as in correlations / associations using IOP.  
The pre-defined subdomains for the VF were: (1) evidence of progression of the VF, which was further subdivided in different outcome measures according to the methodology to measure progression, (2) rate of VF progression/ slope and lastly (3) time to VF progression, which was also classified according to the methodology used.  A similar classification of subdomains was used for other clinical outcomes. Descriptive statistical analysis was undertaken. 
Results
12 Cochrane Reviews and 9 Protocols were identified.  IOP was reported as an outcome in 11 Cochrane Reviews and 5 Protocols, while VF was only reported in 8 Reviews and 3 Protocols (see Table 1). The number of outcomes reported by each Review/Protocol comes to 118 in total.  It does not mean that there were 118 different outcomes.  More than one Review/Protocol may have used the same outcome. Both IOP and safety outcome measures were reported the same numbers of times (n=40, 34%of all outcomes). Anatomical and VF outcomes were less commonly reported, and persistence/adherence to therapy was only reported once (see Table 2).
Amongst the IOP outcome subdomains, a composite definition of success/failure using IOP (e.g., IOP with or without medication, or a pre-defined target IOP, or a percentage reduction of IOP) was the commonest to be reported (n=14, 35% of IOP outcomes). This was followed by other definition of success/failure (e.g., IOP with a pre-specified number of postoperative medications) (n=12, 30% of IOP outcomes) (see Table 3). 
Evidence of the VF progression (according to the pre-defined definitions) was the only reported VF subdomain (see Table 4). Among the safety outcomes, visual acuity (VA) was the most common variable reported (n=16, 40% of safety outcomes) (see Table 5). Optic nerve head (ONH) morphology was the most frequently reported amongst the anatomical outcomes (n=10, 62% of reported anatomical outcomes). Surgical outcomes (postoperative surgical interventions, e.g. needling) were recorded 7 times in 7 Reviews and 1 Protocol, while ocular / systemic haemodynamics as well as aqueous humour dynamics have never been reported as an outcome in the Cochrane Reviews and Protocols.
Regarding those Reviews and Protocols that specified a primary or main outcome IOP was chosen as a primary outcome in 6 Reviews and 5 Protocols - target IOP being the commonest one (n= 8, 20 % of primary outcomes). VF was reported as a primary outcome in 7 Reviews and 2 Protocols.  Each of ONH morphology/RNFL thickness and anterior chamber angle were reported as a primary outcome in two publications each. 
Patient reported quality of life measures were recorded 12 times (in 6 Reviews and 6 Protocols); they were reported only once as a primary outcome. Economic outcome was identified in one Review and three Protocols (see table 1) 
Discussion
To the best of our knowledge, this is the first study that addresses the selection and variability of clinical outcome measures in glaucoma. We identified 13 Cochrane Reviews and 9 Protocols published in Cochrane Eyes and Vision Group (CEVG) library assessing different interventions for glaucoma management.
There was a large heterogeneity with a variety of descriptions within individual clinical outcomes.  This variability was greatest for IOP and safety outcome measures, the most commonly used outcomes. On the other hand, this diversity of outcome selection was less obvious in VF subdomains, where VF progression was the only used VF criteria. Similarly, in the published literature over a 5-year period (between 2001-2005), Rotchford et al identified variability in reporting of IOP success rates in glaucoma surgical trials. The authors concluded that there were nearly as many different IOP-related deﬁnitions of success after glaucoma surgery as there were articles on the subject, and more than 70% of deﬁnitions appeared in only a single article. The definition used influenced the quoted success rate after trabeculectomy, making interpretation of and comparison between published results extremely difficult. Rotchord et al recommended that standardisation of published outcome parameters after glaucoma surgery is essential to allow meaningful comparisons between different study reports (28).
Variability in outcome measures across clinical trials hinders evaluations of the effectiveness and harms of treatments. If studies do not report the same outcomes, or do not provide transparent definitions, it becomes impossible to accurately synthesise data. The difficulties caused by differences in outcome measurement are well known to systematic reviewers. For example, the five most accessed and the top cited Cochrane Reviews in 2009 all reported problems related to outcomes in eligible trials due to inconsistencies in the outcomes reported in the primary reports (29).
The difficulty of selecting the most appropriate outcomes for use in a clinical trial is reflected in the fact that there is much uncertainty regarding exactly which outcomes to select (30). Some of the factors underlying this uncertainty may include ambiguity regarding which outcome domains are of relevance to patients, unknown performance characteristics of potential outcomes (e.g. reliability), or improvements in general care of patients with emergence of new technologies, with the result that previously used outcomes are no longer relevant (31). The ideal outcome should be based on agreed definitions and described exclusively as regards its efficacy and effectiveness of the interventions permitting useful comparisons. It should be reliable and specific to the interventions as well as relevant to clearly identifiable events for the user, i.e. relevant to clinical practice if measuring endpoints (32) 
Therefore, The Core Outcome Measures in Effectiveness Trials Initiative (3) was launched in January 2010 to address this lack of standardised outcome measures in clinical trials and to develop a minimum set of measures named “core outcome sets”, which include end points to be reported as a minimum in all studies within an area of health (3,30) . There is an expectation that the core outcomes will be reported to allow the results of studies to be compared and combined as appropriate; and that researchers will continue to collect other outcomes as well (33). Core outcome sets would help authors and trialists to present their findings openly and concisely, for example within Summary of Findings tables (2). If implemented, the quality of the evidence provided by the individual studies will be improved by reducing the impact of inappropriate outcome selection.
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Table 1: Outcome domains identified in Cochrane Reviews and Protocols
Review/Protocol	Primary outcomes	Secondary outcomes
Medical interventions for POAG and OHT (Review)
(Vass C, 2007)	VFHealth related quality of life	Improvement of VFReduction of NFL loss & Reduction of ONH cupping Local and systemic side effects 
Medical vs surgical interventions for open angle glaucoma (Review) (Burr J, 2005	VF	IOP reductionProgression of OD damage or NFL lossReduction of LogMAR score Failure of randomised treatment as per a priori
Interventions for improving adherence to ocular hypotensive therapy (Review) (Gray TA, 2009)	Adherence to therapy:Persistence with therapy	IOP reduction Progression of ONH damageProgressive VFLQuality of life measures were collected and reported in association with adherence outcomes 
Neuroprotection for treatment of glaucoma in adults (Review) (Sena DF, 2010	VFIOP	VA IOP: Vertical cup-disc ratioQuality of life measures
Medical interventions for treating PACG (Protocol)(Sankar PS,	IOPVFOptic nerve cupping	Adverse eventsQuality of life measures
Acupuncture for glaucoma(Review)(Law SK, 2007)	VF	Reduction of IOPChange in VAProgression of OD damage or NFL loss
Non-penetrating filtration surgery versus trabeculectomy for open angle glaucoma(protocol) (Eldaly MA,2009)	Successful procedures	Progressive VFLProgression of optic disc damage or NFL lossReduction of Log MAR score Quality of life measures
Peripheral iridotomy for pigmentary glaucoma (Protocol) (Shetty RK,2009)	VFIOP
	Mean VAChange in AC depth Change in iris configuration Mean change in aqueous melanin granule Pigment accumulation in the trabecular meshwork & on the iris PROMs if reported in the original articles
Laser trabeculoplasty for OAG (Review)(Rolim de Moura, 2007)	IOPVFOptic disc	Necessity of adding or changing the medical therapeutic regimen Adverse Events
Needling for encapsulated trabeculectomy filtering blebs (Review) (Feyi-Waboso, 2004)	 IOP	BCVA Number of antiglaucoma medicationsNumber of participants requiring repeat needling/trabeculectomyAdverse events
Interventions for late 
Trabeculectomy  bleb leak (protocol)(Bochmann F, 2009)	 Bleb leak	Recurrence of bleb leak Need for further intervention to control bleb leak Any surgical interventions IOP and number of antiglaucoma medications VA If economic or quality of life data are available from the selected studies these outcomes will be mentioned
Aqueous  shunts for glaucoma (Review)(Minckler D, 2009)	IOP Failure: IOP > 21 mhg on or off medications at 12 mths or complete loss of vision or perormance of additional surgery or loss of the eye	   VA Postoperative hypertensive phase (more than 5 mmhg elevation of IOP above baseline levels)15% reduction from baseline IOP VF Total number of antiglaucoma medications, 
One site versus two site phacotrabeculectomy for POAG (Protocol) (Fulco EAM, 2009)	IOPVA	  Proportion of complete success trabeculectomy Mean IOP VF Progression of OD damage or NFL loss Quality of life measures  Economic data as available in trial reports
Postoperative 5-FU for glaucoma surgery ( Review) (Wormald R, 2009)	Failed Trabeculectomy.Failure was defined as the need for repeat surgery or uncontrolled IOP ( usually more than 22 mmhg) despite additional topical or systemic medications	          Adverse event rates 
MMC Vs 5-FU for wound healing in glaucoma surgery (protocol)( Clarke JCK, 2009)	Failure of trabeculectomy	      Survival analysis (time to event) for  the given definition of failure
Beta radiation for glaucoma surgery (Review) (Kirwan JF, 2009)	Failed trabeculectomy: : proportion of failed trabeculectomy at 12 months or more after surgery(defined as repeat surgery, or uncontrolled IOP > 20 mmhg with or without additional topical or systemic medications)IOP	Adverse effects Outcomes relating to quality of life or patient’s perspective of careData relevant to economic evaluation
Limbal versus fornix-based conjunctival trabeculectomy flaps for glaucoma (Protocol)(Al-Hadad C, 2011)	Failed trabeculectomyIOP: Mean IOP at 24 months	Proportion of failed trabeculectomyMean IOP VA Number of medications needed after surgeryAdverse events Quality of life (QoL) as assessed by vision specific QoL questionnaire
Anti-vascular endothelial growth factor for neovascular glaucoma (Protocol)(Simha A, 2009)	IOP	IOP VA Relief of symptoms
Iridectomy or iridotomy for preventing angle-closure glaucoma (Protocol)( Reddy A, 2010)	Incidence of acute attack of angle-closure	 Incidence of PAC 
Laser peripheral iridoplasty for angle-closure (Review) (Ng Ws, 2012	Progression: From narrow angle (IOP< 21) to PAC (IOP>/ 21), and/or
b) From PAC to PACG (with glaucomatous disc damage and/or glaucomatous VF damage)	IOPNumber of antiglaucoma medicationsOpening of the AC angle, Any additional laser or surgical interventionsBCVAQuality of life measures
Lens extraction for chronic angle-closure glaucoma (Review)(Friedman D, 2006)	VFIOP:
	Mean change in depth of the AC from baseline Number of medications to control IOP Gonioscopic findingsVA 
Intraoperative Mitomycin C for glaucoma surgery (Review) (Wilkins M, 2005)	Proportion of failed trabeculectomies
mean IOP after surgery. Failure 	Adverse eventsQuality of life assessments   or patient perspectives
Abbreviations used in table 1: VF, visual field; NFL, nerve fibre layer; ONH, optic nerve head; OD, optic disc; IOP, intraocular pressure; VA, visual acuity; AC, anterior chamber; BCVA, best corrected visual acuity; PAC, primary angle closure, PACG, primary angle closure glaucoma
Table 2: Clinical outcome domains identified in the Cochrane Reviews & Protocols 
Outcome 	Number	Percentages 
IOP 	40 	34% 
VF 	14 	12% 
Safety Outcomes 	40 	34% 
Anatomical 	16 	13% 
Surgical Outcomes 	7 	6% 












Abbreviations used in table 2: IOP, intraocular pressure; VF, visual field

Tabe 3: Intraocular pressure (IOP) outcomes identified in the Cochrane Reviews and Protocols
IOP Outcomes	Number	Percentage
IOP Level: mean IOP/mean diurnal IOP/24 hour IOP	10	25%
IOP Level: others / unspecified criteria	1	2%
IOP change from baseline: mean change of IOP/mean diurnal IOP/change of 24 hour IOP 	3	8%
Composite definition of success/failure: IOP (with or without medication), target IOP, percentage reduction of IOP 	14	35%





Table 4:  Visual field (VF) outcomes identified in the Cochrane Reviews and Protocols
VF Outcomes	Number	Percentages
VF Progression: Global indices/score (MD, PSD, CIGTS score, AGIS score	4	31%




Abbreviations used in table 4:  MD, mean deviation; PSD, pattern standard deviation, CIGTS, Collaborative Initial Glaucoma Treatment Study; AGIS, Advanced Glaucoma Intervention Study

Table 5: Safety outcomes identified in the Cochrane Reviews and Protocols
Safety Outcomes	Number	Percentage
Surface epithelium pathology (clinical exam)	1	3%










Abbreviations used in table 5 : TFCM, tear film confocal microscopy; OGSS, Oxford Grading System Score; BUK, break up time; CCT, central corneal thickness; VA, visual acuity; CS, contrast sensitivity; ERG, electroretinogram
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